NCT00392444 · REGISTRY CONDITION SEARCH

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2014-05-21

This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Objective Response (Partial and Complete) Per RECIST

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Criteria: * Histologically or cytologically confirmed malignant pleural mesothelioma; Advanced or metastatic disease incurable by standard therapies * Measurable disease, defined as at least 1 unidimensionally measurable lesion \>= 20 mm by conventional techniques or \>= 10 mm by spiral CT scan; No sole site of disease in a previously irradiated area unless there has been subsequent evidence of progression; Low-dose, palliative radiotherapy allowed * Meets 1 of the following criteria for prior cytotoxic chemotherapy treatment: Previously treated with 1 platinum-based chemotherapy regimen; Previously untreated (i.e., no prior cytotoxic chemotherapy) * No known brain metastases * ECOG performance status 0-1 * Life expectancy \>= 12 weeks * Platelet count \>= 100,000/mm\^3 * Absolute granulocyte count \>= 1,500/mm\^3 * Bilirubin normal * AST and ALT =\< 2.5 times upper limit of normal * Calcium =\< 3 mmol/L * Creatinine normal OR creatinine clearance \>= 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Patients must reside within a 1.5 hour drive from participating center * Able to take oral medication * No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer, curatively treated in-situ carcinoma of the cervix, or any other curatively treated solid tumor * No known history of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib malate * No QTc prolongation (i.e., QTc interval \>= 500 msec) or other significant ECG abnormalities * No New York Heart Association (NYHA) class III or IV heart failure * Patients with the following histories allowed provided they are asymptomatic with respect to cardiac function and LVEF is normal by MUGA at baseline: Anthracycline exposure, Central thoracic radiation that included the heart, NYHA class II cardiac function * No uncontrolled hypertension (i.e., systolic blood pressure \>= 140 mm Hg or diastolic blood pressure \>= 90 mm Hg) * No cardiac disease within the past 12 months, including any of the following: myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure * No pulmonary embolism within the past 12 months * No cerebrovascular accident or transient ischemic attack within the past 12 months * No bowel obstruction or any condition that would impair the ability to swallow and retain sunitinib malate, including any of the following: gastrointestinal tract disease resulting in an inability to take oral medication, requirement for IV alimentation, active peptic ulcer disease * No serious illness or medical condition that would preclude study treatment including, but not limited to, any of the following: history of significant neurologic or psychiatric disorder that would impair the ability to obtain consent or limit compliance with study requirements, Active uncontrolled infection, Any other medical condition that might be aggravated by treatment, OR; * Serious or nonhealing wound, ulcer, or bone fracture, Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days * No pre-existing hypothyroidism unless euthyroid on medication * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered * At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following: Azole antifungals (e.g., ketoconazole, itraconazole, miconazole), Verapamil, Clarithromycin, HIV protease inhibitors (e.g., indinavir, saquinavir, ritonavir, atazanavir, or nelfinavir) Erythromycin, Delavirdine, Diltiazem * At least 12 days since prior and no concurrent CYP3A4 inducers, including any of the following: Rifampin, Phenytoin, Rifabutin, Hypericum perforatum (St. John's wort), Carbamazepine, Efavirenz Phenobarbital, Tipranavir * At least 4 weeks since prior major surgery and recovered * At least 4 weeks since prior radiotherapy and recovered * At least 12 months since prior coronary/peripheral artery bypass graft or stenting * No prior surgical procedures affecting absorption * No prior radiotherapy that involved \>= 30% of functioning bone marrow * No prior treatment with any other antiangiogenic agents or multitargeted tyrosine kinase inhibitors, including any of the following: bevacizumab, sorafenib tosylate, pazopanib, thalidomide, AZD2171, vandetanib, AMG706, vatalanib, VEGF Trap * No prior angiogenesis inhibitors except epidermal growth factor receptor inhibitors or other noncytotoxic therapy * No other concurrent anticancer therapy or treatment with other investigational anticancer agents * No concurrent combination antiretroviral therapy for HIV-positive patients * No concurrent therapeutic doses of coumadin-derivative anticoagulants (e.g., warfarin); Doses =\< 2 mg/day for prophylaxis of thrombosis or low molecular weight heparin for patients with an INR \< 1.5 are allowed * No concurrent agents with proarrhythmic potential, including any of the following: terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, flecainide
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
intervention Names
Drug: sunitinib malate
label
Treatment (sunitinib malate)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (sunitinib malate)
description
Given orally
name
sunitinib malate
other Names
SU11248
sunitinib
Sutent
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 39
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Number of patients who had objective responses after radiology review
measure
Objective Response (Partial and Complete) Per RECIST
time Frame
Up to 3 years

Full study description

brief Summary: This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth.
detailed Description: PRIMARY OBJECTIVES: I. Assess the efficacy of sunitinib malate, in terms of response rate (complete and partial), in patients with malignant pleural mesothelioma. II. Assess the toxicity, safety, and tolerability of this drug in these patients. III. Assess the duration of response or stable disease, stable disease rate, progression-free survival, and median and overall survival rates. OUTLINE: This is a multicenter, nonrandomized, open-label study. Patients are stratified according to prior cytotoxic chemotherapy (yes vs no). Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-d35d2d017cadb4d04d52
requested nct id
NCT00392444
primary nct id
NCT00392444
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Malignant+Mesothelioma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
payload sha256
b33dd87d9630cac347a8dd7cb568e784a03ca30c28fb7a276764570823e7a787
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-d35d2d017cadb4d04d52
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00392444
occurrences
context exact
NCT00392444
end
11
exact text
NCT00392444
start
0
offset unit
unicode_code_points
query cond
Malignant Mesothelioma
query disease state id
ds-malignant-mesothelioma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-malignant-mesothelioma-000.json
source file sha256
0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
source json pointer
/studies/94/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
45b1b234f4608a19f625096b31d7122274e7356679edb225cd65815ffe9a7480
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Malignant+Mesothelioma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice